Arcus Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 577
- Market Cap
- -
- Website
- http://www.arcusbio.com
- Introduction
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05277012
- Locations
- 🇺🇸
Investigational Site, Lincoln, Nebraska, United States
A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05154136
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05117554
- Locations
- 🇳🇱
Investigational Site, Groningen, Netherlands
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
- Conditions
- MelanomaAdvanced Solid TumorEsophageal CancerNon Small Cell Lung Cancer (NSCLC)Multiple MyelomaCervical CancerLymphoma, Non-HodgkinDiffuse Large B Cell Lymphoma (DLBCL)Gastroesophageal Junction AdenocarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT04772989
- Locations
- 🇺🇸
University of Wisconsin - Madison, Madison, Wisconsin, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
- Conditions
- Squamous Non Small Cell Lung CancerNon Small Cell Lung CancerNonsquamous Non Small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT04736173
- Locations
- 🇺🇸
Hope and Healing Cancer Service, Hinsdale, Illinois, United States
🇬🇷University General Hospital "Attikon", Chaidari, Greece
🇭🇰Humanity and Health Clinical Trial Centre, Hong Kong, Hong Kong
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: m-FOLFOX-6 regimen
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT04660812
- Locations
- 🇫🇷
Clinique Sainte Anne, Strasbourg, France
🇮🇹Ircc Istituto Per La Ricerca E La Cura Del Cancro Di Candiolo Oncologia Medica, Candiolo, Italy
🇮🇹IRCCS - Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis, Castellana Grotte, Italy
A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04575311
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Androgen-Resistant Prostatic NeoplasmsCastration Resistant Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Cancer, Castration-Resistant
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT04381832
- Locations
- 🇺🇸
Florida Cancer Specialists East, West Palm Beach, Florida, United States
🇺🇸The Oncology Institute of Hope & Innovation, Cerritos, California, United States
🇺🇸The University of California, Los Angeles, Encino, California, United States
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
- Conditions
- Squamous Non Small Cell Lung CancerNon Small Cell Lung CancerLung CancerNonsquamous Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT04262856
- Locations
- 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
🇨🇳Chi Mei Hospital, Tainan City, Taiwan
🇰🇷Chungbuk National University Hospital (CBNUH), Cheongju, Korea, Republic of
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT04104672
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States